Ranking Members Waxman and DeGette Urging FTC Scrutiny of Express Scripts-Medco Health Solutions Merger

Mar 20, 2012

Today Rep. Henry A. Waxman and Rep. Diana DeGette sent a letter to Federal Trade Commission Chairman Jon Leibowitz urging that FTC carefully assess specialty pharmacy and exclusive distribution contracts as the agency reviews the proposed merger of pharmacy benefit managers Express Scripts, Inc., and Medco Health Solutions, Inc.

The full text of the letter is below and also available online here.

March 20, 2012

The Honorable Jon Leibowitz
Chairman
Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, DC 20580

Dear Chairman Leibowitz:

We are writing regarding FTC’s review of the proposed merger of Express Scripts, Inc., and Medco Health Solutions, Inc.  We wrote to you last year regarding this merger, asking that FTC closely scrutinize the merger’s impact on consumers and prescription drug costs.[1]      

Press reports indicate that FTC’s review will soon be complete.[2]  We ask you to ensure this review will include a careful assessment of two important pharmacy issues:  specialty pharmacy and exclusive distribution contracts. 

The proposed merger raises concern about specialty pharmacy issues because the combined Medco-Express Scripts entity would control 52% of the specialty drug market and would be more than three times the size of its nearest competitor.[3]  These market share concerns are compounded by the rapid growth of specialty pharmacy services, which, on a per-patient basis, are expected to double between 2010 and 2013.[4]  We urge you to ensure competition is maintained in this important industry sector.

We are also concerned about exclusivity agreements between PBMs and pharmaceutical manufacturers.  These types of arrangements arise when PBMs are able to negotiate with manufacturers to act as sole distributors of drugs, obtaining discounts for their own customers but raising prices for other PBMs and other purchasers.  We raised concerns about these types of arrangements in the context of Medicare Part D in 2011.[5]  We still remain concerned about their impact on both government and private-sector prescription drug costs.  We ask that FTC carefully assess whether the proposed merger will increase the frequency and cost of exclusivity agreements, and if so, take action to prevent the Medco-Express Scripts merger from resulting in abuse of these agreements.

Thank you for your consideration of these requests. 

Sincerely,

 

Henry A. Waxman
Ranking Member

 

Diana DeGette
Ranking Member
Subcommittee on Oversight and Investigations

 

[1] Letter from Reps. Henry A. Waxman, Diana DeGette, and Frank Pallone, Jr., to the Honorable Jon Leibowitz (Sep. 9, 2011) (online at http://democrats.energycommerce.house.gov/index.php?q=news/ranking-membe...).

[2] Express Scripts-Medco Deal Critics Asked by FTC to Suggest Possible Fixes, Bloomberg News (Mar. 10, 2012).

[3] The 2010-2011 Economic Report on Retail and Specialty Pharmacies, Pembroke Consulting (Dec. 2010).

[4] Express Scripts, 2010 Drug Trend Report (Apr. 2011).

[5] Letter from Reps. Henry A. Waxman, Frank Pallone, and Diana DeGette to Reps. Joseph Pitts and Cliff Stearns (Mar. 4, 2011) (online at http://democrats.energycommerce.house.gov/index.php?q=news/democratic-le...).